Compendia Bioscience is a biotechnology company based in Ann Arbor, Michigan, United States. It was founded in 2006 and has since become a leader in the field of oncology research. The company specializes in developing and applying molecular cancer diagnostics to improve patient outcomes.

Compendia Bioscience's headquarters are located in Ann Arbor, Michigan. This strategic location allows the company to collaborate with renowned research institutions and hospitals in the area, such as the University of Michigan Comprehensive Cancer Center. The company offers several products and services that aid in the understanding and treatment of cancer.

Its flagship product, OncoCompass™, is a genomic analysis tool that helps researchers identify biomarkers and potential drug targets. This tool utilizes a comprehensive database of cancer molecular profiles to provide valuable insights into cancer biology. In terms of global operations, Compendia Bioscience has formed strategic partnerships and collaborations with various organizations.

Notably, the company has partnered with pharmaceutical giant Bayer to discover and develop targeted therapies for cancer treatment. This partnership allows for the integration of Bayer's drug discovery expertise with Compendia Bioscience's genomic analysis capabilities. Compendia Bioscience is well-regarded in the market and is considered a key player in the field of oncology research.

Its products and services have gained recognition for their ability to accelerate the development of personalized cancer treatments. The company has carved out a strong market position by offering comprehensive solutions for understanding cancer at a molecular level. Since its inception, Compendia Bioscience has achieved several milestones.

In 2012, the company launched OncoPredict, a prognostic breast cancer test, in collaboration with Life Technologies Corporation. This test provides valuable information about the recurrence risk of breast cancer patients. As of date, there is limited information available regarding the current status, recent events, or any major changes in Compendia Bioscience's strategy or product lineup